PDCD1 and mesothelioma: However, in contrast to the above-mentioned combination therapies, CAR-T cell and anti PD-1 therapy have been studied in patients, and in the case of various solid tumors such as mesothelioma, as discussed earlier, even yield better results than double immune checkpoint inhibitor therapy (125).